Oral tumoractivated chemotherapy--an introduction

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.

ESMO open·2021

A decade of clinical development of PARP inhibitors in perspective.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

Clinical oncology (Royal College of Radiologists (Great Britain))·2017

The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and Failure.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

Targeted oncology·2016

Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

Oncology·2026

A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity.

Oncology·2026

Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Patients with Organ Dysfunction.

Oncology·2026

Fat mass and survival in immunotherapy-treated metastatic renal cell carcinoma patients.

Oncology·2026

Unique stroma of higher-grade pancreatic intraepithelial neoplasia: Fibroblastic cluster formation and CD36-downregulation.

Oncology·2026

Emergency Department Visits after Radiotherapy in Patients with Solid Malignancies: Analysis of Causality and Severity.

Oncology·2026

Related Experiment Videos

Oral tumoractivated chemotherapy--an introduction

Related Concept Videos

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.

A decade of clinical development of PARP inhibitors in perspective.

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

The Influence of Donor and Recipient Gender Incompatibility on Corneal Transplant Rejection and Failure.

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.

Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.

Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.

A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity.

Practical Guide for Managing Philadelphia-Negative Myeloproliferative Neoplasms in Patients with Organ Dysfunction.

Fat mass and survival in immunotherapy-treated metastatic renal cell carcinoma patients.

Unique stroma of higher-grade pancreatic intraepithelial neoplasia: Fibroblastic cluster formation and CD36-downregulation.

Emergency Department Visits after Radiotherapy in Patients with Solid Malignancies: Analysis of Causality and Severity.

Related Experiment Videos

Oral tumoractivated chemotherapy--an introduction

Related Concept Videos

Related Articles